Search results for "LCS-6 KRAS variant"

showing 1 items of 1 documents

Prognostic role of the LCS6 KRAS variant in locally advanced rectal cancer: results of the EXPERT-C trial

2015

KRAS mutation has been reported as a marker of radio-resistance in rectal cancer and unfavourable outcome in both colon and rectal cancer. This study suggests that a single-nucleotide polymorphism of the KRAS gene (LCS-6 variant) may predict response to neoadjuvant treatment and mitigate the poor prognosis associated with KRAS mutation in locally advanced rectal cancer.

MaleOncologyOrganoplatinum CompoundsColorectal cancermedicine.medical_treatmentLET-7 MICRORNA-BINDINGCetuximabmedicine.disease_causeCOLORECTAL-CANCER3'-UNTRANSLATED REGION0302 clinical medicineAntineoplastic Combined Chemotherapy ProtocolsRectal cancerNeoadjuvant therapySingle-nucleotide polymorphism0303 health sciencesCetuximabCOLON-CANCERHazard ratioCAPOX RegimenChemoradiotherapyHematologysingle-nucleotide polymorphismMiddle AgedCombined Modality TherapyNeoadjuvant TherapyBINDING SITE POLYMORPHISM3. Good healthOxaliplatinLet-7Oncology030220 oncology & carcinogenesis5-FLUOROURACIL/dk/atira/pure/sustainabledevelopmentgoals/good_health_and_well_beingFemaleKRASLife Sciences & Biomedicinemedicine.drugAdultGenetic Markersmedicine.medical_specialtyGenotypeLCS-6 KRAS variantPolymorphism Single NucleotideDisease-Free SurvivalCLINICAL-TRIALProto-Oncogene Proteins p21(ras)03 medical and health sciencesSDG 3 - Good Health and Well-beinglet-7Internal medicineGastrointestinal TumorsBiomarkers TumorKRASmedicineHumansOncology & CarcinogenesisProgression-free survivalrectal cancerneoplasmsCapecitabineAged030304 developmental biologyCancer och onkologiScience & TechnologyRectal Neoplasmsbusiness.industryOriginal Articlesmedicine.diseasedigestive system diseasesMicroRNAsCancer and Oncologybusiness1112 Oncology And CarcinogenesisChemoradiotherapyRASAnnals of Oncology
researchProduct